EHA 2023 | The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, recipient of the José Carreras award at this year’s EHA congress, discusses the history of the award before speaking about the history of treatments, particularly immunotherapy, in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Prof. Foà covers multiple studies, from as early as the 1970s to an ongoing GIMEMA trial, focusing on the use of tyrosine kinase inhibitors (TKIs) in combination with blinatumomab and the movement towards chemotherapy-free, transplant-free treatment approaches for patients with Ph+ ALL. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
